Filing Flows › Maxcyte (MXCT) › R&D spending
Maxcyte (MXCT) R&D spending by quarter
Maxcyte's R&D spending was $4.3M in Q2 2026 (second quarter 2026), +10% from Q1 2026. Over the last 7 quarters it ranged from $3.3M (Q4 2025) to $6.3M (Q2 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.3M | +10% | -32% |
| Q1 2026 | $3.9M | +16% | -35% |
| Q4 2025 | $3.3M | -37% | -28% |
| Q3 2025 | $5.3M | -15% | — |
| Q2 2025 | $6.3M | +6% | — |
| Q1 2025 | $5.9M | +28% | — |
| Q4 2024 | $4.6M | — | — |
Q2 2026 at a glance
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Maxcyte's R&D spending?
Maxcyte's R&D spending was $4.3M in Q2 2026 (second quarter 2026), +10% from Q1 2026.
How has Maxcyte's R&D spending changed?
Over the last 7 quarters it ranged from $3.3M (Q4 2025) to $6.3M (Q2 2025).